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To assess the long-term risk of developing cancer
among heart transplant recipients compared to the
Canadian general population, we carried out a retro-
spective cohort study of 1703 patients who received
a heart transplant between 1981 and 1998, identi-
fied from the Canadian Organ Replacement Register
database. Vital status and cancer incidence were de-
termined through record linkage to the Canadian Mor-
tality Database and Canadian Cancer Registry. Cancer
incidence rates among heart transplant patients were
compared to those of the general population. The ob-
served number of incident cancers was 160 with 58.9
expected in the general population (SIR = 2.7, 95% CI
= 2.3, 3.2). The highest ratios were for non-Hodgkin’s
lymphoma (NHL) (SIR = 22.7, 95% CI = 17.3, 29.3), oral
cancer (SIR = 4.3, 95% CI = 2.1, 8.0) and lung cancer
(SIR = 2.0, 95% CI = 1.2, 3.0). Compared to the general
population, SIRs for NHL were particularly elevated in
the first year posttransplant during more recent calen-
dar periods, and among younger patients. Within the
heart transplant cohort, overall cancer risks increased
with age, and the 15-year cumulative incidence of all
cancers was estimated to be 17%. There is an excess of
incident cases of cancer among heart transplant recip-
ients. The relative excesses are most marked for NHL,
oral and lung cancer.
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Introduction
Heart or cardiac transplantation is a well-established pro-
cedure to treat patients with end-stage heart disease or
severe coronary artery disease (1). In the United States,
the number of people living with a functioning heart allo-
graft at year-end increased from 13 829 in 1997 to 18 018
in 2005 (2). As of June 15, 2007, 1-year survival rates were
87.4% for men and 85.5% for women, while 5-year sur-
vival rates were 78.7% for men and 75.9% for women
(3). In Canada, patient and graft survival have continued
to increase in the last decade (4). Heart transplants are
now the third most common organ transplant operation
with 1633 heart transplants between 1997 and 2006 (5).
One-year survival rates of patients with a heart transplant
rose from 82.9% in 1995 to 86.9% in 2005, while 5-year
survival rates rose from 72.5% in 1995 to 82.7% in 2001
(6,7).
It is known that the improvement in survival of patients
following heart transplantation is hampered by a high in-
cidence of cancer (8,9). Posttransplant malignancies have
been shown to occur in over 15% of patients with long-
term follow-up (10–12). The most commonly reported can-
cers are skin cancer and posttransplant lymphoprolifera-
tive disorders (PTLD) (13). Some studies have also shown
that the risk of lung cancer was increased among cardiac-
transplant patients resulting in a poor prognosis (14,15).
Immunosuppressive drugs have been recognized as the
major factor contributing to the increased incidence of can-
cer in transplant recipients (16).
There have been few large studies of the incidence of can-
cer following heart transplantation. Most published stud-
ies have relied on patient data collected from a single
study centre, and the number of patients has been rela-
tively small (10,12,17,18). Therefore, these studies are not
able to characterize precisely the long-term risks of devel-
oping rarer forms of cancer, and moreover, there may be
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constraints in identifying incident cancers among those
who have moved to other regions. Recently, a multi-centre
Italian study found increased risks of cancer among a co-
hort of 724 patients following heart (n = 682) or lung
(n = 42) transplantation (19). The overall standardized in-
cidence ratio in these patients relative to the general pop-
ulation was 2.6 (95% CI: 2.1–3.2), an excess higher than
that found for renal transplant patients in the same co-
hort. More recently, patterns of cancer incidence in a large
cohort of 3393 Spanish patients were described (20), how-
ever, analyses of the cohort were restricted to internal co-
hort comparisons.
The objective of this study was to compare long-term can-
cer risks among heart transplant recipients to the Canadian
population, and to other types of transplant patients drawn
from the same national registry.
Materials and Methods
Study population
The Canadian Organ Replacement Registry (CORR) is a national organ re-
placement registry that contains information on virtually all Canadian pa-
tients who have undergone organ transplantation since 1981. We used this
database to assemble a heart transplant population-based cohort, compris-
ing those patients who received their initial heart transplant between 1981
and 1998. Demographic variables extracted from the database included
date of birth, sex, province of residence, race/ethnicity, primary heart dis-
ease, comorbid conditions and the underlying disease that contributed to
heart failure (5,21).
After excluding those individuals who were diagnosed with cancer before
transplantation, we identified a total of 1908 individuals who had received
heart transplantation between 1981 and 1998. Consistent with previous
analyses (18,22), patients who died within 30 days of transplantation were
excluded from analysis. We also excluded patients who had developed
a cancer within the first 30 days after transplantation, as these cancers
were assumed to be preexisting and unrelated to the surgery (22). Addi-
tionally, all patients who were diagnosed with nonmelanoma skin cancer
after transplantation were excluded as Canadian Cancer Registries (CCR) do
not consistently record nonmelanoma skin cancers. These cancers occur
relatively frequently and are often treated successfully without requiring
hospitalization. As a result, it would be difficult to differentiate between
excesses in heart transplant patients attributable to the transplantation and
excesses due to enhanced surveillance of this patient population. We ex-
amined patterns of cancer incidence in a total of 1703 patients who re-
ceived a heart transplant and who were cancer-free 30 days after receiving
a transplant. The follow-up period started after the first 30 days following
transplantation.
Ascertainment of health outcomes
The Generalized Record Linkage System (GRLS) (23) was used to link the
personal identifiable information of cohort members to the national can-
cer and mortality databases. The GRLS is a probabilistic linkage proce-
dure, which compares common fields in the two files to be linked, assigns
weights to the resulting links, and calculates total weights. Records with
a sufficiently high weight are accepted as a match. This methodology has
been used extensively in Canada for more than two decades. Canadian
national income tax files were linked to help evaluate death searches and
confirm vital status.
Deaths among heart transplant patients were determined by linking the
CORR database to the Canadian Mortality Database (CMDB) (24). The
CMDB contains death data across Canada from 1950 onwards. Validation
studies of record linkage that have used GRLS methodology to ascertain
vital status in the CMDB, have demonstrated that the potential number of
missed deaths is small given the available personal identifying information
(25,26). These previous studies found that the probability of correctly iden-
tifying deceased and living subjects from record linkage to CMDB was 98%
and close to 100%, respectively.
Incident cancer cases among the heart transplant patients were identified
by record linkage of the personal identifying information to the Canadian
Cancer Registry (CCR) database (27). Since 1969, the CCR has provided
information on all Canadian residents who have been diagnosed and con-
firmed with cancer, excluding squamous and basal cell skin cancer. It has
been estimated that the CCR captures at least 95% of all incident cancer
cases (except nonmelanoma skin cancer) in Canada (28). In this study, our
risk estimates are based on the incidence of primary cancers, and there-
fore, patients diagnosed with cancer were censored at the time of their
initial diagnosis. More precisely, in our study follow-up extended until the
earliest date of a cancer diagnosis, death, or the end date of December 31,
1998. Where no death or cancer link was found, it was assumed that the
person was alive or cancer-free as of December 31, 1998.
Statistical analysis
The incidence rates of cancers in heart transplant patients were compared
with those in the Canadian general population using the standardized in-
cidence ratio (SIR). The SIR is the ratio of observed to expected incident
cancer, where ‘expected’ refers to the number expected to occur if heart
transplant patients were subject to the same cancer risk as the general pop-
ulation. The Poisson distribution was used to determine 95% confidence
intervals (CI) for the SIRs (29). To adjust for differences in the age and sex
distribution between the two populations, as well as changes in cancer in-
cidence rates over time, the numbers of person-years (PYs) and observed
cases of incident cancers in the cohort were tabulated by age, sex and cal-
endar period. Expected counts were determined by multiplying incidences
for these same strata by the corresponding PYs. Absolute excess risk ex-
pressed per 10 000 patients per year, was also calculated by subtracting
the expected number of cases from the observed number of cases and
dividing by the PYs at risk. Nonmelanoma skin cancer was excluded from
the analysis because of its underreporting in CCR.
Stratified analyses were then performed to examine variations in risk ac-
cording to age at transplantation (<35, 35–49, 50–59 and ≥60), sex, time
since transplantation (30 days–<1 year, 1–4 years, 5–9 years and ≥10 years),
and year of transplantation (1981–1989, 1990–1992, 1993–1995 and 1996–
1998). This required tabulating the PY of follow-up within each of these
strata, which was done using the DATAB module in the Epicure software
program (30).
Internal cohort comparisons were made using the Cox regression model to
evaluate the effects of several covariates simultaneously on the long-term
risk of developing cancer. Age, sex and transplant year were used to ex-
amine the independent effects on the risk of all cancers and non-Hodgkin’s
lymphoma (NHL) after heart transplantation. Additionally, competing risks
survival methodology, based on formulae presented by Gooley et al. (31),
were applied to estimate the cumulative incidence of developing certain
cancers after transplantation. Following this method, persons who die or
develop another form of cancer are no longer at risk of developing the in-
dex cancer (as a primary cancer). This differs from the complement of the
Kaplan–Meier survival estimator which treats patients who die as censored
and hence implicitly assumes that they remain at risk to develop the index
cancer in the future (32).
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Finally, as a subanalysis and as a follow-up to our previous work (33,34),
we compared cancer incidence rates in heart transplant recipients to those
in kidney and liver transplant patients which also derived from the CORR
database. We then fitted two Cox models, adjusting for age, sex and calen-
dar period, one for all cancers and one for NHL.
Results
In the CORR database, the first heart transplantation oc-
curred in July 1982. A total of 1703 heart transplant pa-
tients were alive and cancer-free 30 days after transplan-
tation. The cohort was predominantly male (82.5%), and
the majority of transplantations (64.8%) were performed
among patients between the ages of 40 and 59 (Table 1).
The overall cancer incidence rate per 1000 PYs was 15.4.
Hereafter, all rates are reported per 1000 PYs of follow-
up. The three most frequent types of cancer were NHL
(5.7), lung cancer (2.1) and oral cancer (1.0). For overall can-
cers, the incidence per 1000 PYs was higher among men
than among women (15.7 vs. 13.9). Figure 1 depicts the
mean age at the time of diagnosis of cancer and the mean
follow-up interval between the date of transplantation and
a diagnosis of cancer. Incident cancers were identified in
137 men and 23 women. Among those who were diag-
nosed with cancer, the mean age with standard error (SE)
at the time of a cancer diagnosis was 54.4 (SE, 1.1) years,
and the mean length of time from the transplantation to
diagnosis was 57.5 (SE, 3.3) months. Patients with a di-
agnosis of prostate cancer, lung cancer or oral cancer had
a higher mean age and a relatively longer length of time
from transplantation to a diagnosis of cancer. Patients with
a diagnosis of NHL had a lower mean age and a shorter
length of time from transplantation.
There were 160 observed cases of cancer in the study ver-
sus the 58.9 cases that were expected based on general
population rates (SIR = 2.7, 95% CI = 2.3, 3.2) (Table 2).
All cancers, oral cancer, lung cancer, NHL and multiple
myeloma had significantly elevated ratios (SIR > 1.0) in
this patient population, and the highest was for NHL (SIR
= 22.7, 95% CI = 17.3, 29.3). Overall, the cohort study
group experienced an excess of 9.8 cancer cases per 1000
PYs, and NHL contributed the most to this excess (5.4).
Table 3 shows the SIRs for all cancer sites combined and
for NHL among heart transplant patients according to age
at surgery, period of surgery, follow-up interval and sex.
The SIRs were the highest among younger transplant pa-
tients and among patients with less than a year (and at
least 30 days) of follow-up, both for all cancers and for
NHL. Women had higher rates than men.
Table 1: Characteristics of 1908 patients who received a heart transplant between 1981 and 1998. Canadian Organ Replacement Registry
Database
No. of Person-years
Characteristic patients % of follow-up %
Age at surgery (in years)
<10 78 4.1 285.3 2.8
10–<20 91 4.8 509.1 4.9
20–<30 120 6.3 815.3 7.9
30–<40 169 8.9 1019.0 9.8
40–<50 472 24.7 2829.1 27.3
50–<60 765 40.1 4037.4 38.9
≥60 213 11.2 877.4 8.5
Gender
Male 1575 82.5 8720.0 84.1
Female 333 17.5 1652.5 15.9
Year of surgery
1981 to 1989 650 34.1 5099.1 49.2
1990 to 1992 416 21.8 2467.1 23.8
1993 to 1995 491 25.7 2035.7 19.6
1996 to 1998 351 18.4 770.8 7.4
Follow-up interval1
< 30 day2 205 10.7 143.3 1.4
30 d–<1 year 174 9.1 1464.0 14.1
1–< 5 years 579 30.3 5027.0 48.5
5–<10 years 624 32.7 3044.3 29.3
10 years + 326 17.1 694.0 6.7
Total 1908 100.0 10 372.6 100.0
Total (excluding first 30 days) 1703 88.7 10 368.9 100.0
1The person-year calculation in each follow-up interval was the contributions of all patients to the interval not just the patients whose
follow-up ended in that interval.
2These subjects were excluded in the estimation of cancer risks.
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Figure 1: Mean age at the time of
cancer diagnosis and mean inter-
val to develop cancers from heart
transplantation for various cancers
patients.
Results from the Cox regression model indicate higher can-
cer risks with older patients after adjustment for sex, and
calendar period for all cancers. The data suggest an in-
creased risk of cancer among those who received a trans-
plant more recently; however, the category-specific hazard
ratios, relative to before 1990, were not statistically signifi-
cant. For NHL, there were statistical differences in risk be-
tween those who underwent transplantation before 1990
and those operated on in 1995–1998 (Table 4). When cal-
endar period was fit as a continuous variable, the incidence
rate increased by 7.0% and 11.1% per year for all cancers
(HR = 1.07; p = 0.01) and NHL (HR = 1.11; p = 0.02),
respectively.
The cumulative incidence of cancer in heart transplant pa-
tients by time since transplantation is shown in Figure
2. Unlike typical survival analysis methods (e.g. Kaplan–
Meier estimator), cumulative incidence estimates properly
account for the competing risks of death and diagnoses
for other cancers. At 15 years posttransplantation, the
Table 2: Standardized Incidence Ratios (SIRs)1 for selected cancers among patients undergoing heart transplantation between 1981 and
1998, CORR
Observed Expected Absolute
Cancer site2 ICD-9 cases cases SIR 95% CI excess risk3
All cancers 160 58.9 2.7 2.3, 3.2 97.5
Oral 140–149 10 2.3 4.3 2.1, 8.0 7.4
Colorectal 153–154 5 7.7 0.6 0.2, 1.5 −2.6
Pancreas 157 4 1.3 3.1 0.8, 7.9 2.6
Larynx 161 3 1.2 2.5 0.5, 7.3 1.7
Lung 162 22 11.1 2.0 1.2, 3.0 10.5
Malignant melanoma 172 5 1.8 2.8 0.9, 6.5 3.1
Bladder 188 3 2.7 1.1 0.2, 3.2 0.3
Kidney 189 6 2.1 2.9 1.0, 6.2 3.8
NHL 200, 202 59 2.6 22.7 17.3, 29.3 54.4
Multiple myeloma 203 5 0.7 7.1 2.3, 16.7 4.1
Male cancers
Prostate 185 15 11.3 1.3 0.7, 2.2 4.2
Female cancers
Breast 174 3 2.7 1.1 0.2, 3.2 1.8
Others 25 11.4 2.2 1.4, 3.2
1Individuals were followed from 30 days after the date of their first heart transplant until the earliest date associated with a diagnosis of
an incident cancer, death, or December 31, 1998.
2Excludes all secondary or later primary cancers following the first malignancy diagnosed subsequent to transplantation.
3Absolute excess risk expressed per 10 000 patients per year; was calculated by subtracting the expected number of cases from the
observed number of cases and dividing by the person-years at risk (10 368.9 for total, 8717.3 for male and 1651.6 for female).
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Table 3: Standardized incidence ratios (SIRs) for all cancer sites and non-Hodgkin’s lymphoma among patients who received a heart
transplant, by transplantation date, follow-up intervals, gender and age at transplantation
All cancers NHL
Characteristic O E SIR (95% CI) O E SIR (95% CI)
Transplantation date1
1981–1989 72 29.7 2.4 (1.9, 3.1) 23 1.3 17.7 (11.2, 26.5)
1990–1992 47 13.1 3.6 (2.6, 4.8) 16 0.6 26.7 (15.2, 43.3)
1993–1995 27 11.7 2.3 (1.5, 3.4) 13 0.5 26.0 (13.8, 44.5)
1996–1998 14 4.4 3.2 (1.7, 5.3) 7 0.2 35.0 (14.0, 72.1)
Follow-up interval
30 days–<1 year 33 6.1 5.4 (3.7, 7.6) 24 0.3 80.0 (51.2, 119.0)
1–<5 years 55 25.8 2.1 (1.6, 2.8) 13 1.2 10.8 (5.8, 18.5)
5–<10 years 59 20.8 2.8 (2.2, 3.7) 17 0.9 18.9 (11.0, 30.2)
≥10 years 13 5.7 2.3 (1.2, 3.9) 5 0.2 25.0 (8.1, 58.3)
Sex
Male 137 51.9 2.6 (2.2, 3.1) 51 2.4 21.3 (15.8, 27.9)
Female 23 7.0 3.3 (2.1, 4.9) 8 0.3 26.7 (11.5, 52.5)
Age at transplantation (years)
<35 20 1.0 20.0 (12.2, 30.9) 15 0.1 150.0 (83.9, 247.4)
35–<50 38 10.7 3.6 (2.5, 4.9) 18 0.7 25.7 (15.2, 40.6)
50–<60 83 32.9 2.5 (2.0, 3.1) 23 1.4 16.4 (10.4, 24.7)
≥60 19 14.3 1.3 (0.8, 2.1) 3 0.5 6.0 (1.2, 17.5)
Total 160 58.9 2.7 (2.3, 3.2) 59 2.6 22.7 (17.3, 29.3)
O = observed number of incident cancers; E = expected number based on Canadian general population rates.
1The cut-off points for transplantation dates are not even due to the minimum number (3) of observed cases required by Statistic Canadian
for public release.
cumulative incidence for all cancers was estimated to be
17%, indicating that 17% of a cohort of heart transplant
recipients would be expected to be diagnosed with can-
cer within 15 years (acknowledging that the patients may
die first). Focusing on the cancers for which elevated SIRs
were observed, Figure 2 also presents cumulative inci-
dence estimates for NHL (6% after 15 years) and lung
cancer (3% after 15 years). Thus, 6% of heart transplant
patients are expected to have a primary diagnosis of NHL
within 15 years, accounting for the fact that a patient may
die or be diagnosed with a different type of cancer first.
Discussion
This is a nationwide cohort study of 1703 heart transplant
patients with 10 368.9 PYs of follow-up. The study de-
scribes precisely the long-term risk of developing cancer,
including rare types of cancer. In addition, it allowed us
to characterize variations in risk by transplantation date,
age at transplantation, sex and duration of follow-up. The
CORR database was linked to Canadian national tax files to
validate the resident status. This reduced the potential for
outcome misclassification and yielded a better estimation
Table 4: Cox proportional hazards model for risk factors for developing all cancers and NHL subsequent to heart transplantation
All cancers NHL
Risk factor1 Patient no. HR 95% CI p-Value Patient no. HR 95% CI p-Value
Age at HT (years)
<40 24 1 – – 18 1 – –
40–<60 117 1.9 1.2, 3.0 0.004 38 0.8 0.5, 1.4 0.5
≥60 19 2.4 1.3, 4.5 0.005 3 0.4 0.1, 1.5 0.2
Sex
Female 23 1 – – 8 1 – –
Male 137 1.0 0.7, 1.6 0.9 51 1.3 0.6, 2.8 0.5
Calendar period2
1983–1990 90 1 – – 27 1 – –
1991–1994 46 1.2 0.8, 1.8 0.4 20 1.8 1.0, 3.5 0.06
1995–1998 24 1.6 0.9, 2.7 0.08 12 2.4 1.1, 5.2 0.03
HR = hazard ratio; HT = heart transplantation.
1All covariates were fit simultaneously in the same model.
2A similar analysis was conducted by coding the calendar period as a continuous variable, then the significance of year was found for all
cancers and NHL (data not shown).
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Figure 2: Cumulative incidence of
all cancers, NHL and lung cancer,
by time since heart transplantation
between 1981 and 1998.
of PYs. The CORR was then linked to two mandatory re-
porting systems, the CCR and the CMDB. They both have
a high level of data quality and close to 100% coverage
(25–28). Moreover, it is unlikely that heart transplantation
patients would move outside the country due to the nature
of health care services provided in Canada. Therefore, our
estimates of cancer risks are unlikely to be biased by cases
lost to follow-up.
Until recently, only limited data were collected on heart
transplant recipients. Most studies have focused on the
high frequencies of cancers without reference to the gen-
eral population (8,10–12,17,35). Our study is among the
very few studies that compare the risk of developing spe-
cific cancers in heart transplant recipients to the general
population. The findings are consistent with those noted in
a multi-centre Italian study of 724 heart or lung transplant
patients (19). For all cancer sites combined, they found an
SIR of 2.6 (95% CI: 2.1–3.2), with an elevated risk for non-
Hodgkin’s lymphoma (SIR = 17.9, 95% CI: 11.2–27.0) and
lung cancer (SIR = 2.8, 95% CI: 1.8–4.2). Their study, how-
ever, identified a total of only 95 incident cancers among
heart or lung transplant patients, and therefore had limited
ability to describe risks of developing rarer types of cancer.
Our study has shown an elevated risk of cancer among
heart transplant patients. The SIR for all cancers was 2.7
times higher compared to the general Canadian popula-
tion. This ratio appears to be lower than the relative risk
of 7.1 among heart and/or lung transplant recipients in a
single institution in Australia (9). A study from Sweden (22)
also found a high SIR of 4.0 for all cancers in patients
who underwent transplantation of the kidney, liver, heart
or other organs. The possible reason for our lower figures
is the exclusion of nonmelanoma skin cancer due to its
underreporting in Canadian cancer registries. It is difficult
for Cancer Registries to collect all cases of nonmelanoma
skin cancer since most patients are treated without requir-
ing hospitalization in Canada. As a result, we cannot pro-
vide SIRs for nonmelanoma skin cancer and for all cancers
including nonmelanoma skin cancer. Otherwise, the true
rate ratio would be exaggerated. Our incidence rates of
overall cancers per 1000 PYs are similar to those in a study
using the International Society for Heart & Lung Transplan-
tation registry data (36), but lower than those in a study
from Spain likely due to the exclusion of nonmelanoma
skin cancer (20).
An interesting observation of the study is the increased
SIRs for all cancers and NHL in the more recent time pe-
riods. A closer examination of time trends in the overall
cancer incidence in both the cohort and the general popu-
lation found that rates decreased in both groups, but at a
greater rate in the general population. One possible expla-
nation could be differences in the major risk factors in the
two populations with better control of major risk factors in
the general population.
Using the same national population-based CORR database,
the SIR is slightly higher among heart transplant patients
than among kidney or liver transplant cases in Canada
(33,34). A study from the United States with 674 solid-
organ transplant recipients at a single center reported a
similar result (12). Furthermore, based on the Cox model
comparing each of heart transplant and liver transplant pa-
tients to kidney transplant recipients, cardiac patients were
at a significant 30% increased risk of developing cancer
from all causes combined (HR = 1.30; p = 0.004). In con-
trast, liver recipients had the same risk of developing can-
cer (all causes) as kidney recipients (HR = 1.00; p = 0.80).
The Italian study (19) showed similar higher SIRs for heart
transplant patients relative to kidney transplant patients. A
nationwide cohort study in Sweden also revealed that the
SIR of cancer was higher among patients who received
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other organ transplants than those who underwent kidney
transplantation (22). This may be explained by the more ag-
gressive immunosuppressive therapy in heart and/or lung
transplant recipients than in those receiving other organs
(37) or it could be due to the fact that those who require a
heart transplant are more likely to have engaged in harmful
behaviors (e.g. smoking) than those who required a kidney
transplant, placing them at a higher risk of cancer at older
ages. There is evidence to suggest that an elevated can-
cer risk among organ transplant recipients is due to the
use of immunosuppressive drugs. For heart transplant pa-
tients, this risk is even higher as higher doses of immuno-
suppressive drugs are used. A meta-analytic study (38)
asserted that immune deficient patients and immunosup-
pressed transplant recipients suffer a similar elevated risk
of cancer. This suggests that immune deficiency, whether
induced by a virus or a drug, may be one of the domi-
nant risk factors for the development of cancer. Moreover,
preexisting cancer is a contraindication for a heart trans-
plantation, which is not always the case for a kidney or
liver transplantation.
The approximate 23-fold increased risk of NHL among
heart transplant patients compared with the general pop-
ulation in our study supports the findings from other pub-
lished reports (9,39). The association between Epstein-Barr
virus (EBV) and the occurrence of lymphoproliferative disor-
ders is known (35,39). In our study, data collection on test-
ing for EBV was incomplete; therefore, it was not possible
to determine this association. Also, in contrast with other
series (14,40), female gender and a younger age seem to
represent more risk of developing cancer after heart trans-
plantation. In addition the SIR for cancer was highest in the
first year of follow-up. It most likely results from more ag-
gressive immunosuppression in the first year to avoid the
severe consequences of graft failure due to rejection (39).
Furthermore, based on the same CORR database, heart
and liver transplant patients had a significantly elevated
risk of NHL, (HR = 3.50 and 2.2, respectively) relative to
kidney transplant patients. It is worth noting that this study
period ends in 1998. However, many changes in immuno-
suppressive protocols have been made since then. Addi-
tional studies with more current data should confirm this
finding. Studies are also needed to identify how much of
the excess found in the early part of follow-up is due to
preexisting cancer at the time of transplantation.
In order to exclude patients with preexisting neoplasias,
similar cohort studies have censored patients in whom can-
cer was diagnosed in the first month after organ transplan-
tation (19,22). To be comparable with these study results,
we also excluded patients who had a cancer diagnosed in
the first 30 days after transplantation. However, the def-
inition of an appropriate exclusion period is not straight-
forward. The excluded period from the Spanish study was
extended to 3 months after heart transplantation (20). In
order to expand the comparability, we conducted a sensi-
tivity analysis by excluding also 3- and 6-month intervals
after transplantation, respectively. The SIRs showed non-
appreciable differences among the three approaches.
The types of drugs used for the induction and maintenance
of immunosuppression and the duration of treatment influ-
ence both the incidence and the type of cancer although
immunosuppression does not entirely account for a causal
link to cancer (41,42). In contrast, another immunosup-
pressive drug, Sirolimus (rapamycin), has been shown re-
cently to prevent tumors and even to cause established
tumors to regress (43). Our study was unable to evaluate
these associations as information on immunosuppressive
drugs was not collected for CORR. Nevertheless, the main
conventional risk factors for the development of posttrans-
plant cancer, particularly skin, lung and oral cancer have
been identified and include smoking, sun damage, anal-
gesic abuse and previous malignancy (16). Since there
was a lack of information on lifestyle factors in the CORR
database, we cannot accurately identify risk exposure in
the patients. An enhanced database would be required to
confirm the impact of immunosuppressive drugs, as well
as to identify how known risk factors operate differently in
this population versus the general population.
In conclusion, the population-based design of this study as
well as an ability to ascertain incident cancers for a follow-
up interval up to 18 years provides important insights on
cancer risks in a heart transplant population. This study
demonstrates a higher incidence of cancer among heart
transplant recipients relative to the general population. The
relative increases are the greatest for NHL, oral cancer and
lung cancer. Female, young age and the immediate post-
transplant period are identified as the most common fac-
tors associated with the occurrence of cancer. It will be
informative to conduct enhanced cancer surveillance, es-
pecially for NHL, oral cancer and lung cancer after heart
transplantation including data on innovative immunosup-
pression strategies.
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